You searched for "atrophy"
Feb/Mar 2015 Quiz 1
1 February 2015
| Shweta Kaushik, Eleni Nikita
|
EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
A 79-year-old male presented to the ophthalmic emergency department with a three week history of left eye pain. He also reported visual deterioration in the left eye over the same period. He suffered from degenerative myopia, with his spectacle prescription...
Atropine treatment for myopia in western countries – rationale
This preliminary study sets out the rationale, methodology and participant baseline characteristics for the Western Australia Atropine for the Treatment of Myopia (WA-ATOM). It is a double masked randomised placebo-controlled trial. This study is designed to be combined with the...
Myopia progression with atropine and different treatment lenses
This study aimed to determine the effectiveness of low dose atropine at inhibiting myopia progression, the possible additive potency of this treatment combined with either of two peripheral defocus contact lenses over three years of therapy, and whether there was...Neovascular AMD: fresh recommendations underline standards of best practice
1 December 2013
| Rod McNeil
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...
Corporate M&A pace gathers momentum
1 October 2019
| Rod McNeil
|
EYE - General
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...
Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference
Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress
2 August 2024
| Rod McNeil
|
EYE - General
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...
Atropine penalisation for amblyopia in the UK
The authors aimed to determine the current clinical practice of atropine penalisation (AP) in the UK, to identify perceived barriers limiting use of AP as a first line treatment and ascertain whether any of the barriers could be resolved. An...
Choice of cycloplegia regime
The purpose of this randomised control trial (RCT) was primarily to compare the refractive outcome of atropine 0.5% (A) instilled twice daily at home 2.5 days before measurement versus two drops of 1% cyclopentolate (CC) in one eye versus one...
Effect of low-dose atropine on myopia progression
A randomised study to evaluate the effects of 0.01% and 0.02% atropine eye drops (one drop once nightly to both eyes) on myopic progression, pupil diameter and accommodative amplitude in myopic patients. Four hundred myopic children were divided into three...
Changes in the choroid after atropine for amblyopic and fellow eyes
The purpose of this study was to compare the effects of atropine on the thickness and structure of the choroid between amblyopic and fellow eyes. This study included 16 patients: five males, 11 females. Median age at ocular coherence tomography...
